Faculty Advisor

Heilman, Destin

Center

University of Massachusetts Medical Center

Abstract

The Hepatitis C virus infects nearly 170 million people worldwide, and is the major cause of hepatitis and liver cancer. The current treatment is a therapy with pegylated interferon and ribavirin, which has severe side effects. Recent addition of HCV NS3/4A protease inhibitors to this therapy has improved HCV treatments, but the severe side effects and rapid emergence of drug resistance limit the effectiveness of this therapy. Therefore, new HCV therapies must be developed that are effective against a broader spectrum of resistant viral variants and HCV genotypes. This project followed the multi-step synthesis of a new variant of the MK-5172 inhibitor, evaluated the synthesis plan, and provided the UMass Medical School with a new inhibitor to test activity against NS3/4A protease variants.

Publisher

Worcester Polytechnic Institute

Date Accepted

April 2013

Major

Chemistry

Project Type

Major Qualifying Project

Accessibility

Unrestricted

Advisor Department

Chemistry and Biochemistry

Advisor Program

Chemistry and Biochemistry

Project Center

University of Massachusetts Medical Center

Your accessibility may vary due to other restrictions.

Share

COinS